- Crystalline forms of valbenazine ditosylate
-
Disclosed herein are new crystalline forms of valbenazine ditosylate designated Form D and Form E, which are characterized using one or more analytical methods, such as X-ray Powder Diffraction analysis. Further disclosed herein are crystalline Form D valbenazine ditosylate in the form of a dichloromethane solvate, and crystalline Form E valbenazine ditosylate in the form of a hydrate. Also disclosed are pharmaceutical compositions comprising these new crystalline forms, and methods of using those compositions for the treatment of various disease states and conditions, including hyperkinetic disorder, such as drug-induced tardive dyskinesia and Tourette's syndrome.
- -
-
Page/Page column 9-10
(2020/07/09)
-
- CRYSTALLINE VALBENAZINE FREE BASE
-
The present disclosure generally relates to crystalline valbenazine. The present disclosure also generally relates to a pharmaceutical composition comprising crystalline valbenazine, as well of methods of using crystalline valbenazine in the treatment of
- -
-
Page/Page column 19
(2018/08/03)
-
- SUBSTITUTED 3-ISOBUTYL-9, 10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-A] ISOQUINOLIN-2-OL COMPOUNDS AND METHODS RELATING THERETO
-
Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol compounds are disclosed that are inhibitors of the vesicular monoamine transporter 2 (VMAT2). The compounds of this invention have the structure (I): wherein R1 is as defined herein, including stereoisomers and pharmaceutically acceptable salts and solvates thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use in a subject in need thereof.
- -
-
Page/Page column 14-15
(2008/12/05)
-